Retinal Vessel Density and Retinal Nerve Fiber Layer Thickness: A Prospective Study of One-Year Follow-Up of Patients with Parkinson’s Disease
暂无分享,去创建一个
[1] Xue Li,et al. Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease , 2023, Journal of the Neurological Sciences.
[2] M. Breteler,et al. Visual impairment and retinal and brain neurodegeneration: A population‐based study , 2023, Human brain mapping.
[3] Yu Deng,et al. Evaluation of retina and microvascular changes in the patient with Parkinson’s disease: A systematic review and meta-analysis , 2022, Frontiers in Medicine.
[4] A. Regev,et al. Temporal single-cell atlas of non-neuronal retinal cells reveals dynamic, coordinated multicellular responses to central nervous system injury , 2022, bioRxiv.
[5] M. Hallett,et al. Eye Movement Disorders in Movement Disorders , 2022, Movement disorders clinical practice.
[6] J. Qu,et al. Retinal Dopamine D2 Receptors Participate in the Development of Myopia in Mice , 2022, Investigative ophthalmology & visual science.
[7] B. Lacoste,et al. From Neurodevelopmental to Neurodegenerative Disorders: The Vascular Continuum , 2021, Frontiers in Aging Neuroscience.
[8] P. Chan,et al. Prevalence of Parkinson's Disease: A Community‐Based Study in China , 2021, Movement disorders : official journal of the Movement Disorder Society.
[9] Dan Zhang,et al. Retinal Flow Density Changes in Early-stage Parkinson’s Disease Investigated by Swept-Source Optical Coherence Tomography Angiography , 2021, Current eye research.
[10] R. Zhao,et al. MSC-Derived Exosomes can Enhance the Angiogenesis of Human Brain MECs and Show Therapeutic Potential in a Mouse Model of Parkinson's Disease , 2021, Aging and disease.
[11] Wan-Hazabbah Wan Hitam,et al. Retinal Nerve Fiber Layer and Macular Thickness in Parkinson's Disease Patients , 2021, Cureus.
[12] M. Zappia,et al. Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease. , 2021, Parkinsonism & Related Disorders.
[13] M. Tsolaki,et al. Ocular biomarkers and their role in the early diagnosis of neurocognitive disorders , 2021, European journal of ophthalmology.
[14] X. Mu,et al. Genetic control of retinal ganglion cell genesis , 2021, Cellular and Molecular Life Sciences.
[15] M. Droździk,et al. Arterial Blood Pressure Variability and Other Vascular Factors Contribution to the Cognitive Decline in Parkinson’s Disease , 2021, Molecules.
[16] Joan W. Miller,et al. Retinal applications of swept source optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) , 2021, Progress in Retinal and Eye Research.
[17] Jia-Yi Li,et al. Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation , 2021, Scientific Reports.
[18] Cason B. Robbins,et al. Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease. , 2020, JAMA ophthalmology.
[19] Yujie Wang,et al. Central retina changes in Parkinson’s disease: a systematic review and meta-analysis , 2020, Journal of Neurology.
[20] P. Yu-Wai-Man,et al. Optical Coherence Tomography Angiography Reveals Distinct Retinal Structural and Microvascular Abnormalities in Cerebrovascular Disease , 2020, Frontiers in Neuroscience.
[21] Lu Shen,et al. Combination of optical coherence tomography (OCT) and OCT angiography increases diagnostic efficacy of Parkinson's disease. , 2020, Quantitative imaging in medicine and surgery.
[22] R. Monastero,et al. Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study , 2020, Journal of Neurology.
[23] B. Franco,et al. α-synuclein overexpression in the retina leads to vision impairment and degeneration of dopaminergic amacrine cells , 2020, Scientific Reports.
[24] A. Xie,et al. Association Between Stroke and Parkinson’s Disease: a Meta-analysis , 2020, Journal of Molecular Neuroscience.
[25] Mahmut Atum,et al. Retinal morphological changes during the two years of follow-up in Parkinson's disease. , 2020, Ideggyogyaszati szemle.
[26] Benjamin R. Kummer,et al. Associations between cerebrovascular risk factors and parkinson disease , 2019, Annals of neurology.
[27] W. Kwapong,et al. CHARACTERIZATION BY FRACTAL DIMENSION ANALYSIS OF THE RETINAL CAPILLARY NETWORK IN PARKINSON DISEASE. , 2019, Retina.
[28] Benedict Michael,et al. Faculty Opinions recommendation of Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[29] Z. Çolakoglu,et al. Functional and morphological assessment of ocular structures and follow-up of patients with early-stage Parkinson’s disease , 2019, International Ophthalmology.
[30] V. Baekelandt,et al. Retinal α-synuclein deposits in Parkinson’s disease patients and animal models , 2019, Acta Neuropathologica.
[31] M. Cordeiro,et al. Oculo‐visual abnormalities in Parkinson's disease: Possible value as biomarkers , 2018, Movement disorders : official journal of the Movement Disorder Society.
[32] Jianhua Wang,et al. Retinal Microvascular Impairment in the Early Stages of Parkinson's Disease. , 2018, Investigative ophthalmology & visual science.
[33] M. Carbonelli,et al. Patterns of Retinal Ganglion Cell Damage in Neurodegenerative Disorders: Parvocellular vs Magnocellular Degeneration in Optical Coherence Tomography Studies , 2017, Front. Neurol..
[34] James G. Fujimoto,et al. The Definition, Rationale, and Effects of Thresholding in OCT Angiography. , 2017, Ophthalmology. Retina.
[35] M. Jin,et al. MDS clinical diagnostic criteria for Parkinson’s disease in China , 2017, Journal of Neurology.
[36] Jose A Crespo,et al. Evaluation of Progressive Visual Dysfunction and Retinal Degeneration in Patients With Parkinson's Disease. , 2017, Investigative ophthalmology & visual science.
[37] G. Malaguarnera,et al. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain , 2016, Acta neuropathologica communications.
[38] I. Selesnick,et al. The avascular zone and neuronal remodeling of the fovea in Parkinson disease , 2015, Annals of clinical and translational neurology.
[39] Ivan Bodis-Wollner,et al. α‐synuclein in the inner retina in parkinson disease , 2014, Annals of neurology.
[40] F. Ascaso,et al. Development of a prediction formula of Parkinson disease severity by optical coherence tomography , 2014, Movement disorders : official journal of the Movement Disorder Society.
[41] Aysu Şen,et al. Effects of Levodopa on Retina in Parkinson Disease , 2014, European journal of ophthalmology.
[42] L. Pablo,et al. Retinal thinning and correlation with functional disability in patients with Parkinson's disease , 2013, British Journal of Ophthalmology.
[43] Axel Petzold,et al. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment , 2012, PloS one.
[44] C. Clarke,et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[45] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[46] A. Albanese. Diagnostic criteria for Parkinson's disease , 2003, Neurological Sciences.
[47] T. Chan-Ling,et al. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. , 2000, Investigative ophthalmology & visual science.
[48] C. Mao,et al. Progressive Changes in the Retinal Structure of Patients with Parkinson's Disease. , 2018, Journal of Parkinson's disease.
[49] M. Schwartz,et al. The retina as a window to the brain—from eye research to CNS disorders , 2013, Nature Reviews Neurology.